The purpose of this study is to examine 4 different therapeutic approaches towards improving the 3 year event free survival from 6% to 35% in newly diagnosed metastatic Rhabdomyosarcoma patients.
Thank you for your interest, but this study is recruiting by invitation only.
United States (Nationwide)
Patrick Thompson
Pediatrics - Hematology/Oncology
Clinical or Medical
Interventional
Cancer (Pediatric Cancers, Sarcoma (bone and soft tissue))
20-1755
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
